Adocia SA (ADOCY)
OTHER OTC:ADOCY
Top Page
Adocia
(OTC:ADOCY)
Select Model
Select Model
Rating:41Neutral
Price Target:
$7.50
▲(7.30% Upside)
Action:ReiteratedDate:11/22/25
Adocia's overall stock score is heavily impacted by its poor financial performance, characterized by persistent losses and financial instability. Technical analysis indicates bearish momentum, and valuation metrics highlight unprofitability. These factors combine to produce a low overall score, suggesting significant risks for potential investors.
Positive Factors
Proprietary delivery platform
Adocia’s proprietary drug delivery technologies create a durable competitive asset by improving established therapeutics’ PK profiles. A platform approach can drive repeat licensing, attract pharma partners, and scale across indications, supporting long-term partnership revenue streams.
Negative Factors
Negative shareholders' equity
Negative equity signals structural balance-sheet weakness and limited financial flexibility. It constrains access to traditional financing, increases creditor risk, and can force dilutive capital raises or onerous terms, impairing the company’s ability to sustain long-term development programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary delivery platform
Adocia’s proprietary drug delivery technologies create a durable competitive asset by improving established therapeutics’ PK profiles. A platform approach can drive repeat licensing, attract pharma partners, and scale across indications, supporting long-term partnership revenue streams.
Read all positive factors
Adocia (ADOCY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$105.03M
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue Growth1882.51%
EPS Growth62.37%
CountryUS
Employees78
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding19,607,805
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.37
Price to Book (P/B)-54.61
Price to Sales (P/S)18.10
P/FCF Ratio-10.65
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue8.10
Enterprise Value/Gross Profit79.77
Enterprise Value/Ebitda19.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Adocia Business Overview & Revenue Model
Company Description
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platfo...
How the Company Makes Money
Adocia generates revenue primarily through collaborative agreements and partnerships with larger pharmaceutical companies. These partnerships often involve licensing deals where Adocia receives upfront payments, research funding, and milestone pay...
Adocia Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
25
Negative
Cash Flow
35
Negative
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 9.32M | 2.15M | 11.45M | 1.44M | 841.00K |
| Gross Profit | 8.20M | 1.39M | 9.61M | 180.00K | -616.00K |
| EBITDA | -6.91M | -19.35M | -3.58M | -19.35M | -20.03M |
| Net Income | -9.32M | -21.16M | -6.90M | -22.75M | -23.32M |
Balance Sheet | |||||
| Total Assets | 27.02M | 24.96M | 30.61M | 30.05M | 45.17M |
| Cash, Cash Equivalents and Short-Term Investments | 7.53M | 12.96M | 17.42M | 15.16M | 28.11M |
| Total Debt | 11.83M | 13.09M | 33.21M | 34.48M | 28.20M |
| Total Liabilities | 30.11M | 31.87M | 43.58M | 43.87M | 38.83M |
| Stockholders Equity | -3.09M | -6.91M | -12.97M | -13.81M | 6.33M |
Cash Flow | |||||
| Free Cash Flow | -15.84M | -5.11M | -15.15M | -19.59M | -22.06M |
| Operating Cash Flow | -15.61M | -4.95M | -14.99M | -19.23M | -21.85M |
| Investing Cash Flow | -258.00K | -138.00K | 21.86M | -361.00K | -204.00K |
| Financing Cash Flow | 10.44M | 629.00K | -4.61M | 6.64M | 6.51M |
Adocia Technical Analysis
Negative
6.99
Price Trends
7.09
Negative
7.68
Negative
8.11
Negative
Market Momentum
-0.58
Positive
26.80
Positive
11.47
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADOCY, the sentiment is Negative. The current price of 6.99 is above the 20-day moving average (MA) of 6.06, below the 50-day MA of 7.09, and below the 200-day MA of 8.11, indicating a bearish trend. The MACD of -0.58 indicates Positive momentum. The RSI at 26.80 is Positive, neither overbought nor oversold. The STOCH value of 11.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ADOCY.
Adocia Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $282.98M | -1.51 | -53.83% | ― | -10.57% | 1.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $137.19M | -0.86 | -55.02% | ― | -46.92% | 20.26% | |
50 Neutral | $504.84M | -8.24 | -122.12% | ― | -100.00% | -0.58% | |
44 Neutral | $173.56M | -3.96 | -204.14% | ― | ― | -22.06% | |
41 Neutral | $105.03M | -8.77 | 306.12% | ― | 1882.51% | 62.37% |
* Healthcare Sector Average
ADOCY
Adocia
5.38
1.67
45.05%
ACHV
Achieve Life Sciences
3.26
1.12
52.34%
FATE
Fate Therapeutics
1.18
0.26
28.40%
CBIO
Crescent Biopharma
18.32
-0.90
-4.68%
CCCC
C4 Therapeutics
2.90
1.60
123.08%
ACTU
Actuate Therapeutics, Inc.
1.92
-5.46
-73.98%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.